NeoGenomics unveiled a leadership transition with Warren Stone named CEO effective Jan 4, 2027, while Tony Zook moves to executive chair. Preliminary Q3 revenue ≈$209 million and NGS testing up ~28% YoY; 2026 revenue guidance remains $802–$806 million, with a net loss of -$42M to -$34M and adjusted EBITDA of $56–$58M. The stock dropped about 12% on the news as investors weigh execution risk and potential growth catalysts ahead.
NEO is in Phase 18, consolidating for over 850 days. Signs of a breakout remain weak until at least August 2026. Historical trends show risk of declining to $18 price level. Weak Guna Triads indicate lack of bullish momentum. Investors should hold off on new positions in NEO.
